NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Bullfrog AI Holdings, Inc. (BFRG) Stock Analysis

Bullfrog AI Holdings, Inc. (BFRG) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

BFRG

$0.50

+$0.01 (+2.65%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BFRG with… →

BFRG Key Statistics

As of Sep 4, 2026
Trading
Open
$0.51
Previous Close
$0.49
Day's Range
0.49–0.51
52-Week Range
0.43–2.04
Volume
55.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−2.72
Valuation
Market Cap
$9.33M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
31.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.47
Financials (FY)
Revenue (FY)
$116.67K
Net Income (FY)
−$6.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
18.54M
1-Year Return
−57.01%
Dividend and dates
Avg Volume
156.98K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BFRG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.04%
2025−55.85%
2024−38.65%
2023 (partial year)−49.85%

As of September 4, 2026.

BFRG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$116.67K−$6.50M−5569.6%
2024$0.00−$6.99M—
2023$65.00K−$5.36M−8239.8%
2022$10.00K−$2.80M−28024.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$116.67K$21.89K−$6.59M−$6.50M−5569.6%
2024$0.00$0.00−$7.24M−$6.99M—
2023$65.00K$59.80K−$5.37M−$5.36M−8239.8%
2022$10.00K$9.20K−$2.46M−$2.80M−28024.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BFRG Valuation vs Health Information Services Median

Median of 53 stocks
MetricBFRGHealth Information Services medianvs median
P/S ratio31.232.6611.7x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Bullfrog AI Holdings, Inc. (BFRG) is capitalised at $9.33M on the latest close. The company sits in the Healthcare sector, in the Health Information Services industry. Headcount on file is 9.

The 52-week range on file runs from $0.43 to $2.04. BFRG last closed at $0.50 on September 4, 2026. That is +$0.01 (+2.65%) against the previous close. The latest close sits 18.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $116.67K. The same year closed with a net loss of $6.50M. Profit margin runs at 0%. Trailing earnings per share are −0.47.

Across the 4 fiscal years on file, revenue moves from $10.00K in 2022 to $116.67K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 31.23 times revenue. On price-to-sales that is 11.7 times the Health Information Services median of 2.66. The medians here are taken across 53 Health Information Services companies that report the metric.

Over the trailing twelve months the price has returned −57.01%. Measured over 3 years, that is −45.86% a year compounded. Beta against the wider market is reported at −2.72. Annualized volatility over the trailing 3 years is 127.87%.

Growth & Income

No dividend is on file for BFRG.

The strongest complete calendar year on file is 2024 at −38.65%; the weakest is 2025 at −55.85%. So far in 2026 the price is −43.04%.

Peer Comparison

Bullfrog AI Holdings, Inc. (BFRG) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bullfrog AI Holdings, Inc. BFRG $9.33M —
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
Tempus AI, Inc. TEM $11.66B —

The Health Information Services industry average P/E ratio is 41.1x. Bullfrog AI Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 TEM

Tempus AI, Inc.

$11.66B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bullfrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Visit website →